Results 161 to 170 of about 149,933 (301)

Renal dysfunction in symptomatic Waldenström macroglobulinaemia: A nationwide Italian multicentre study

British Journal of Haematology, EarlyView.
Renal dysfunction represents a possible underrecognized complication of symptomatic WM; this condition correlates with adverse global and disease‐specific clinical outcomes. Summary The prognostic significance of impaired renal function in Waldenström macroglobulinaemia (WM) remains poorly defined.
Nicolò Danesin, Francesco Autore, Anna Maria Frustaci, Gianmarco Favrin, Emanuele Cencini, Alessandro Noto, Irene Dogliotti, Jacopo Olivieri, Marcello Riva, Isacco Ferrarini, Anna Maria Barbui, Sara Steffanoni, Dario Marino, Benedetta Puccini, Piero Maria Stefani, Rita Rizzi, Michele Merli, Angela Ferrari, Stefano Luminari, Carlo Visco, Livio Trentin, Andrea Visentin, Annarita Conconi, Simone Ferrero, Marzia Varettoni, Alessandra Tedeschi, Luca Laurenti, Francesco Piazza   +27 more
wiley   +1 more source

Plerixafor plus granulocyte colony-stimulating factor for patients with non-Hodgkin lymphoma and multiple myeloma: Long-term follow-up report [PDF]

, 2018
Bolwell, Brian, Cheverton, Peter D, DiPersio, John F, Horwitz, Mitchell E, Kaufman, Jonathan L, Maziarz, Richard T, McCarty, John M, Micallef, Ivana N, Nademanee, Auayporn P, Stadtmauer, Edward A, Stiff, Patrick J, Struijs, Martin, Vargo, Rita   +12 more
core   +2 more sources

Circulating levels of insulin‐like growth factor I (IGF‐I) and risk of multiple myeloma: An observational and Mendelian randomisation study

British Journal of Haematology, EarlyView.
Summary Evidence for an association between insulin‐like growth factors (IGF) and multiple myeloma (MM) is inconsistent. We examined total IGF‐I concentrations and risk of MM by combining baseline serological data among UK Biobank participants (n = 444 187; 732 incident MM) with a two‐sample Mendelian randomisation (MR) analysis using identified ...
Yolanda Benavente, Sara Hermosa, Nikos Papadimitriou, Alyssa Clay‐Gilmour, Elizabeth E. Brown, Jonathan N. Hofmann, Nathaniel Rothman, Qing Lan, Sonja I. Berndt, Demetrius Albanes, Mark Purdue, Mitchell J. Machiela, Stephen J. Chanock, Parveen Bhatti, Wendy Cozen, Aaron Norman, Susan L. Slager, James R. Cerhan, Vincent Rajkumar, Shaji K. Kumar, Celine M. Vachon, Anne J. Novak, Thomas M. Habermann, Brian K. Link, Gilles Salles, Herve Ghesquieres, Paige M. Bracci, Elizabeth Holly, Rosalie G. Griffin, Michelle A. T. Hildebrandt, Roel C. H. Vermeulen, P. Martijn Kolijn, Henrik Hjalgrim, Karin Ekström Smedby, Harindra Jayasekara, Simon Cheah, Alain Monnereau, Yu Chen, Alan Arslan, Yawei Zhang, Nicola J. Camp, Douglas W. Sborov, Afaf E. G. Osman, Elad Ziv, Immaculata De Vivo, Vijai Joseph, Lauren R. Teras, Alpa V. Patel, Eleanor Kane, Claire M. Vajdic, Adrien Guilloteau, Pierluigi Cocco, Laia Alemany, Juan Sainz, James McKay, Brenda M. Birmann, Delphine Casabonne   +56 more
wiley   +1 more source

Adriamycin, Vinblastine and Dacarbazine With Immunotherapy Achieves Complete Metabolic Response in a Patient With Classical Hodgkin Lymphoma and Dyskeratosis Congenita. [PDF]

J Hematol
Slapnicar C, Lala P, Lee S, Zandi S, Trinkaus M.   +4 more
europepmc   +1 more source

Exploiting ALK inhibition in anaplastic large cell lymphoma: Biological rationale and therapeutic integration

British Journal of Haematology, EarlyView.
Summary Mature T‐cell lymphomas comprise a heterogeneous group of aggressive non‐Hodgkin lymphomas with limited therapeutic options in the relapsed or refractory setting. Among them, anaplastic lymphoma kinase (ALK)‐positive anaplastic large cell lymphoma (ALCL) represents a biologically distinct subtype driven by constitutive activation of ALK fusion ...
Santino Caserta, Enrica Antonia Martino, Mamdouh Skafi, Maria Eugenia Alvaro, Antonella Bruzzese, Nicola Amodio, Marco Fiorillo, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +13 more
wiley   +1 more source

Disease burden of hematological malignancies worldwide, in China and in the United States based on the GLOBOCAN 2022 and Global Burden of Disease 2021 data. [PDF]

Chin Med J (Engl)
Lin M, Sun W, Huang X, Zhao X.
europepmc   +1 more source

Checkpoint inhibitors, obinutuzumab plus PET‐adapted ultra‐low dose nodal radiotherapy yield high efficacy in treatment‐naïve follicular lymphoma: Results from the phase II ‘FLUORO’ study

British Journal of Haematology, EarlyView.
Summary Follicular lymphoma (FL) first‐line chemoimmunotherapy yields high efficacy but serious toxicity in 65% of patients. In high tumour burden treatment‐naïve FL, we aimed to exploit known immunostimulatory and cytotoxic properties of combination checkpoint inhibition (atezolizumab) and obinutuzumab (6 cycles) with positron emission tomography (PET)
Arina Martynchyk, Geoffrey Chong, Richard Khor, Denise Lee, Sze Ting Lee, Andrew M. Scott, Anneke C. Grobler, Belinda A. Campbell, Thanuja Thachil, Kate Manos, Genevieve Douglas, Alexandra Romano, Jodie B. Palmer, Melinda Burgess, Colm Keane, Eliza A. Hawkes   +15 more
wiley   +1 more source

Global trends in the burden of non-Hodgkin Lymphoma: a comprehensive analysis from 1990 to 2045. [PDF]

Cancer Causes Control
Wang S, Wang J, Lin J.
europepmc   +1 more source

Incidence of severe COVID‐19 in patients with chronic lymphocytic leukaemia or indolent B‐cell non‐Hodgkin lymphoma who received vaccination and pre‐exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi

British Journal of Haematology, EarlyView.
Gian Matteo Rigolin, Stefano Soddu, Riccardo Dondolin, Anna Maria Frustaci, Ilaria Scortechini, Francesca Romana Mauro, Francesco Angotzi, Marina Motta, Lydia Scarfò, Andrea Mengarelli, Annamaria Giordano, Sara Martinelli, Caterina Patti, Paolo Sportoletti, Alessandro Sanna, Nilla Maschio, Rossella Riccioni, Clara Virginia Viganò, Agostino Tafuri, Alfonso Piciocchi, Paola Fazi, Stefano Luminari, Andrés J. M. Ferreri, Guido Gini, Paolo Ghia, Antonio Cuneo   +25 more
wiley   +1 more source

Deciphering the full spectrum of Castleman diseases based on a cohort of 700 patients in a western country

British Journal of Haematology, EarlyView.
The spectrum of Castleman diseases has expanded over the past three decades. The phenotype of the diseases varies not only among the three major types but also according to the patient ancestry. Summary Under the Castleman disease (CD) eponym, three distinct diseases sharing common pathological features have been described over time.
Eric Oksenhendler, Marion Malphettes, Véronique Meignin, David Boutboul, Lionel Galicier   +4 more
wiley   +1 more source